Doptelet
Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe
Sobi receives NICE recommendation for Altuvoct in severe haemophilia A
Approximately 7,700 people in England are living with the genetic bleeding disorder
Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A
The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults
Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study
Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder
Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study
There are currently no treatments that target the underlying cause of C3G or IC-MPGN
Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children
The rare bleeding disorder affects approximately one in every 5,000 male births annually
Takeda’s mezagitamab shows promise in immune thrombocytopenia
The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually
Sobi receives EC marketing authorisation for Altuvoct in haemophilia A
The rare bleeding disorder affects approximately one in every 5,000 male births annually
Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A
The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies
Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH
The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria
Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A
The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting
Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia
The late-stage LUNA 3 study results will be presented at a medical congress later this year